Literature DB >> 9169177

Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.

A J Mocroft1, J D Lundgren, A d'Armino Monforte, B Ledergerber, S E Barton, S Vella, C Katlama, J Gerstoft, C Pedersen, A N Phillips.   

Abstract

BACKGROUND: There are known to be wide differences in the prognosis of patients with a diagnosis of AIDS. In this study of 6578 patients with AIDS form 17 European centres, we develop a ranking of AIDS-defining illnesses, and determine how well this ranking holds after adjustment for potential confounding variables.
METHODS: Survival from each AIDS-defining event was calculated and ranked using Kaplan-Meier estimation of median survival. Cox proportional hazards models with each disease modelled as a time dependant covariate were used to determine the risk of death after each diagnosis, before and after adjustment for potential confounders.
RESULTS: Median survival after an initial AIDS-defining diagnosis of progressive multifocal leukoencephalopathy and malignant lymphoma was particularly poor (2 and 5 months respectively), while the longest median survival occurred after initial AIDS-defining illnesses of Kaposi's sarcoma and extrapulmonary tuberculosis (17 and 22 months respectively) Patients diagnosed with a primary brain lymphoma had shorter median survival times than patients with a peripheral lymphoma (median survival of 1 month and 4 months respectively P < 0.0001). In general, median survival in patients with cutaneous Kaposi's sarcoma (skin, oral) was between two and four times longer than patients with systemic involvement The ranking of diseases was found to be generally similar after adjustment for all potential confounders.
CONCLUSIONS: AIDS-defining events can be grouped into three categories with median survival after diagnosis of < 6 months. 6-12 months and > 12 months. The assigned ranking of disease would not be altered by prognostic factors such as age or CD4 lymphocyte count. These results have important implications in the design of clinical trials and patient management.

Entities:  

Mesh:

Year:  1997        PMID: 9169177     DOI: 10.1093/ije/26.2.400

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  21 in total

1.  Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA).

Authors:  R Thiébaut ; D Malvy; C Marimoutou; F Davis
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Authors:  Katherine Huppler Hullsiek; Birgit Grund
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

3.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

4.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Authors:  Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

5.  Opportunistic Infections and Mortality: Still Room for Improvement.

Authors:  Henry Masur; Sarah W Read
Journal:  J Infect Dis       Date:  2015-06-03       Impact factor: 5.226

6.  Global HIV neurology: a comprehensive review.

Authors:  Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

7.  High levels of divergent HIV-1 quasispecies in patients with neurological opportunistic infections in China.

Authors:  Yulin Zhang; Feili Wei; Qi Liang; Wei Ding; Luxin Qiao; Fengli Song; Lifeng Liu; Sufang Yang; Ronghua Jin; Jianhua Gu; Ning Li; Dexi Chen
Journal:  J Neurovirol       Date:  2013-07-10       Impact factor: 2.643

Review 8.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Authors:  Matthew P Fox; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2010-06       Impact factor: 2.622

9.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Authors:  Amanda Mocroft; Jonathan A C Sterne; Matthias Egger; Margaret May; Sophie Grabar; Hansjakob Furrer; Caroline Sabin; Gerd Fatkenheuer; Amy Justice; Peter Reiss; Antonella d'Arminio Monforte; John Gill; Robert Hogg; Fabrice Bonnet; Mari Kitahata; Schlomo Staszewski; Jordi Casabona; Ross Harris; Michael Saag
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

10.  Brain magnetic resonance imaging screening is not useful for HIV-1-infected patients without neurological symptoms.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Katsuji Teruya; Tsuyoshi Tajima; Yoshimi Kikuchi; Kanehiro Hasuo; Shinichi Oka
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-21       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.